argenx ADR saw a positive improvement to its Relative Strength (RS) Rating on Monday, rising from 88 to 91.
IBD's proprietary rating tracks market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the best-performing stocks typically have an 80 or better RS Rating as they begin their biggest price moves.
How To Use Stock Charts To Stay Profitable And Protected
argenx ADR is building a consolidation with a 678.21 entry. See if the stock can clear the breakout price in volume at least 40% higher than normal.
argenx ADR showed 0% EPS growth last quarter. Sales rose 82%. The company is expected to report its latest earnings and sales numbers on or around May 8.
argenx ADR earns the No. 9 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and GeneDx Holdings are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
